
Loading, please wait...

Loading, please wait...

Ornithine transcarbamylase deficiency is the most common inherited urea cycle disorder encountered in pediatric metabolic medicine. Clinicians primarily recognize this X-linked condition because it triggers severe hyperammonemia and progressive neurologic impairment. However, emerging clinicopathologic studies reveal a significant predisposition to primary liver lesions. Pathologists now identify benign and malignant hepatic neoplasms in young pediatric cohorts with this metabolic disease. Consequently, clinicians must recognize these structural parenchymal alterations early to guide long-term hepatobiliary surveillance and therapy.
The ornithine transcarbamylase enzyme catalyzes the condensation of carbamoyl phosphate with ornithine to synthesize citrulline within hepatocyte mitochondria. Because deficient enzymatic activity arrests the urea cycle, toxic levels of ammonia rapidly accumulate in the blood and central nervous system. In addition, defective nitrogen handling alters intermediary metabolic cascades inside the hepatic parenchyma. Historically, clinicians documented hepatic adenomas and carcinomas predominantly in adult cohorts who survived recurrent metabolic crises. However, recent pediatric series reveal that liver tumors can also manifest during early childhood. These findings suggest that chronic biochemical disarray fosters cellular stress and sustained proliferative signaling. Therefore, modern management requires practitioners to monitor structural liver changes alongside systemic metabolic parameters.
Comprehensive pathology reviews demonstrate that primary liver tumors in affected children span a diverse morphologic spectrum. Specifically, investigations identify focal nodular hyperplasia, hepatocellular adenoma, and conventional hepatocellular carcinoma. In some instances, surveillance scans or native liver explant examinations detect incidental solitary or multiple adenomas. Furthermore, patients with concurrent genetic cancer predispositions, such as Li-Fraumeni syndrome, can develop both focal nodular hyperplasia and early-onset carcinoma. These malignant transformations can appear during the first decade of life. Consequently, clinicians should never assume pediatric metabolic livers harbor purely homogeneous tissue. Instead, teams must evaluate all focal hepatic lesions with precise imaging and histopathology.
Researchers are elucidating the genetic and molecular drivers that promote tumor development in this population. Because the OTC gene resides on the X chromosome, female carriers exhibit varied clinical severity through lyonization. Notably, advanced RNA sequencing demonstrates extreme biased allelic expression in certain neoplastic foci. Lesional tissue and adjacent non-neoplastic liver cells can express predominantly the mutant allele rather than the wild-type counterpart. Moreover, defective mitochondrial urea synthesis increases oxidative damage and alters gene transcription. In patients carrying concomitant germline mutations, such as TP53 alterations, abnormal metabolic flux accelerates clonal expansion. Thus, non-random X-inactivation combined with secondary somatic hits drives pediatric oncogenesis.
Beyond distinct tumors, the background parenchyma in these patients reveals characteristic microscopic changes. Pathologists identify hepatic glycogenosis as the single most prevalent non-neoplastic histologic finding, affecting more than ninety percent of reviewed livers. Under light microscopy, swollen hepatocytes show cytoplasmic pallor and prominent plant-like cell borders resembling glycogen storage disease. In contrast, significant macrovesicular steatosis and advanced architectural fibrosis occur infrequently in pediatric specimens. Therefore, pathologists must distinguish clear-cell changes caused by glycogenosis from true lipid accumulation or ballooning degeneration. Recognizing this prominent glycogen deposition prevents diagnostic confusion when evaluating native biopsy or explant specimens.
Because pediatric patients face lifelong risks of parenchymal neoplasms, multidisciplinary teams must institute structured follow-up protocols. Baseline hepatobiliary imaging with high-resolution abdominal ultrasonography provides a safe initial screening strategy. However, magnetic resonance imaging with liver-specific contrast agents offers superior sensitivity for distinguishing adenomas, focal nodular hyperplasia, and carcinoma. Additionally, biochemical surveillance should incorporate regular serum alpha-fetoprotein measurements during metabolic clinic visits. When clinicians identify suspicious nodules, surgical and hepatology teams should deliberate promptly to formulate intervention plans. Early identification allows timely surgical resection or prioritizes candidates for orthotopic liver transplantation before malignancy metastasizes.
Hepatic glycogenosis represents the predominant non-neoplastic histologic alteration, occurring in more than ninety percent of pediatric specimens. Histologically, hepatocytes appear diffusely swollen with pale, cleared cytoplasm caused by excess glycogen storage. In contrast, severe macrovesicular steatosis and advanced bridging fibrosis remain uncommon in young children. Pathologists must recognize this pattern to avoid misinterpreting metabolic changes as formal storage diseases or steatohepatitis.
Chronic disruption of mitochondrial nitrogen processing induces cellular stress, reactive oxygen species formation, and altered gene transcription. In female carriers, skewed X-chromosome inactivation leads to predominant expression of the mutant allele in hepatic tissue. Furthermore, coexisting genetic mutations, such as germline TP53 variants, can accelerate cellular proliferation. Together, these combined biochemical and genetic alterations promote clonal expansion and tumor formation.
Specialists recommend serial abdominal ultrasonography combined with regular serum alpha-fetoprotein measurements during routine metabolic follow-up. If screening reveals a focal hepatic nodule, clinicians should promptly obtain dynamic liver protocol magnetic resonance imaging. This advanced imaging modality differentiates focal nodular hyperplasia from hepatocellular adenoma and overt carcinoma, thereby guiding timely medical, surgical, or liver transplantation interventions.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or establish a doctor-patient relationship. Healthcare professionals must exercise independent clinical judgment. Refer to the latest local and national guidelines for clinical practice.
References
1. Liu KY et al. Hepatocellular Tumors in Patients With Ornithine Transcarbamylase Deficiency Include Focal Nodular Hyperplasia, Hepatocellular Adenoma, and Hepatocellular Carcinoma. Pediatr Dev Pathol. 2026 Nov 22. doi: 10.1177/10935266261505537. PMID: 43067717.
2. Cheng L, Liu Y, Wang W, Merritt JL, Yeh M. Hepatocellular Adenoma in a Patient with Ornithine Transcarbamylase Deficiency. Case Rep Hepatol. 2019;2019:2313791.
3. Häberle J, Burlina A, Chakrapani A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: First revision. J Inherit Metab Dis. 2019;42(6):1192-1230.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


Ornithine transcarbamylase deficiency, the most common urea cycle disorder, is historically linked to acute hyperammonemia. Recent findings demonstrate that pediatric patients can also develop focal nodular hyperplasia, hepatocellular adenoma, and hepatocellular carcinoma alongside diffuse glycogenosis.
Today

A groundbreaking Bayesian two-stage clinical trial design integrates historical reference data using MAP priors to evaluate biosimilarity and interchangeability efficiently, minimizing patient burden in rheumatoid arthritis studies.
Today

A qualitative study in the Journal of Human Lactation highlights the significant hurdles healthcare workers face when continuing breastfeeding. Inadequate facilities, rigid shift schedules, and lack of institutional policies demand structured workplace lactation support and compliant hospital infrastructure.
Today

A cross-sectional study evaluates the critical intersection between acute surgical pain, kinesiophobia, and fall risks during initial mobilization after cardiac surgery, emphasizing targeted nursing strategies.
Today

A recent cross-sectional analysis reveals that over a quarter of randomized controlled trials for non-specific low back pain face discontinuation or unknown status, while more than 36% of completed trials remain unpublished, exposing notable reporting gaps in spine and musculoskeletal clinical research.
Today

Explore revascularisation strategies in dialysis-dependent chronic limb-threatening ischaemia. This review examines surgical bypass vs endovascular therapy, BEST-CLI trial findings, procedural morbidity, conduit availability, and multidisciplinary decision-making for optimal limb salvage.
Today